Pfizer plans to conduct offering of fixed-rate notes in five parts

By Devika Patel

Knoxville, Tenn., March 4 – Pfizer Inc. intends to offer dollar-denominated fixed-rate notes in five tranches, according to a 424B3 filing with the Securities and Exchange Commission.

The company will sell notes due 2022, 2024, 2029, 2039 and 2049.

The 2022 notes will have a make-whole call. The remaining notes feature a make-whole call and then a par call.

Barclays, Deutsche Bank Securities Inc., Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC are the bookrunners.

Proceeds will be used for general corporate purposes, including to refinance, redeem or repurchase existing debt and repay commercial paper.

The biopharmaceutical company is based in Foster City, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.